Novo Nordisk: Triple agonist UBT251 delivers up to 19.7% mean weight loss after 24 weeks in phase 2 trial in China

Novo Nordisk: Triple agonist UBT251 delivers up to 19.7%... UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo NordiskIn a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to... UBT251 is a triple agonist of the receptors for GLP-1, GIP and glucagon (triple G), being jointly developed by United Biotechnology and Novo NordiskIn a placebo-controlled phase 2 trial in Chinese people with overweight or obesity, UBT251 led to a statistically significant mean weight loss of up to 19.7% after 24 weeksUBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies. Guangdong, China and Bagsværd, Denmark, 24 February 2026 âEUR" The United Laboratori Market Context Stock market movements reflect investor sentiment, corporate earnings, and macroeconomic conditions. Investors should conduct thorough research and consider long-term fundamentals when making investment decisions. Key Takeaways Analyze company fundamentals and market trends for informed decisions Stay informed about economic indicators and central bank policies Maintain diversification across sectors and asset classes Published: February 24, 2026 | Source: Yahoo Finance